Phytopharm Plc has obtained underwriting commitments to increase its share capital by 267% following the announcement in October 2009 of favourable results from two studies of Cogane, the company’s treatment for Parkinson’s disease.
Phytopharm Plc has obtained underwriting commitments to increase its share capital by 267% following the announcement in October 2009 of favourable results from two studies of Cogane, the company’s treatment for Parkinson’s disease.